(Q36944386)

17 August 2017

1 reference

title

The B7 family and cancer therapy: costimulation and coinhibition (English)

1 reference

17 August 2017

2

James P Allison

0 references

author name string

Xingxing Zang

series ordinal

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

published in

Clinical Cancer Research

1 reference

17 August 2017

volume

13

1 reference

17 August 2017

issue

18 Pt 1

1 reference

17 August 2017

page(s)

5271-5279

1 reference

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

17 August 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Murine B7-H3 is a negative regulator of T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

ICOS is critical for CD40-mediated antibody class switching

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

ICOS co-stimulatory receptor is essential for T-cell activation and function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7x: a widely expressed B7 family member that inhibits T cell activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

To be or not to be B7.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7S1, a novel B7 family member that negatively regulates T cell activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-H4, a molecule of the B7 family, negatively regulates T cell immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B70 antigen is a second ligand for CTLA-4 and CD28.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

T-cell co-stimulation through B7RP-1 and ICOS

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Differential T cell costimulatory requirements in CD28-deficient mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

CTLA-4: new insights into its biological function and use in tumor immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Enhancement of CD8+ T cell responses by ICOS/B7h costimulation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-H3 and B7-H4 expression in non-small-cell lung cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

A new member of the immunoglobulin superfamily--CTLA-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Restoring function in exhausted CD8 T cells during chronic viral infection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

LICOS, a primordial costimulatory ligand?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Breaking down the barriers to cancer immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-h4 is highly expressed in ductal and lobular breast cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

ICOS is essential for effective T-helper-cell responses

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-07-1030

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

Identifiers

DOI

10.1158/1078-0432.CCR-07-1030

1 reference

17 August 2017

1 reference